Search

Bexagliflozin

Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.

Deutetrabenazine

Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. … As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease [T28].

Lonafarnib

for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients. … aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.

Human varicella-zoster immune globulin

Human varicella-zoster immune globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). … donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the disease severity in high-risk patients who lack evidence of immunity to varicella and for

Multipotent adult arogenitor cells

The cells for creation of the product are isolated from a qualified donor and expanded on a large scale and then frozen until use. After administration, the cells are cleared from the body over time. … They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic.

Glycerol phenylbutyrate

Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.

Cyd dengue virus serotype 4 live (attenuated) antigen

Treprostinil

[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. … Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension.

Mepenzolate

Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. … It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.

Doxacurium

Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.